Literature DB >> 26904939

Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.

Jianqiang Wu1, Vincent W Keng2, Deanna M Patmore1, Jed J Kendall1, Ami V Patel1, Edwin Jousma1, Walter J Jessen1, Kwangmin Choi1, Barbara R Tschida3, Kevin A T Silverstein4, Danhua Fan4, Eric B Schwartz5, James R Fuchs5, Yuanshu Zou6, Mi-Ok Kim6, Eva Dombi7, David E Levy8, Gang Huang1, Jose A Cancelas9, Anat O Stemmer-Rachamimov10, Robert J Spinner11, David A Largaespada2, Nancy Ratner12.   

Abstract

To identify genes and signaling pathways that initiate Neurofibromatosis type 1 (NF1) neurofibromas, we used unbiased insertional mutagenesis screening, mouse models, and molecular analyses. We mapped an Nf1-Stat3-Arid1b/β-catenin pathway that becomes active in the context of Nf1 loss. Genetic deletion of Stat3 in Schwann cell progenitors (SCPs) and Schwann cells (SCs) prevents neurofibroma formation, decreasing SCP self-renewal and β-catenin activity. β-catenin expression rescues effects of Stat3 loss in SCPs. Importantly, P-STAT3 and β-catenin expression correlate in human neurofibromas. Mechanistically, P-Stat3 represses Gsk3β and the SWI/SNF gene Arid1b to increase β-catenin. Knockdown of Arid1b or Gsk3β in Stat3(fl/fl);Nf1(fl/fl);DhhCre SCPs rescues neurofibroma formation after in vivo transplantation. Stat3 represses Arid1b through histone modification in a Brg1-dependent manner, indicating that epigenetic modification plays a role in early tumorigenesis. Our data map a neural tumorigenesis pathway and support testing JAK/STAT and Wnt/β-catenin pathway inhibitors in neurofibroma therapeutic trials.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26904939      PMCID: PMC4782770          DOI: 10.1016/j.celrep.2016.01.074

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  40 in total

Review 1.  NF1 tumor suppressor gene function: narrowing the GAP.

Authors:  K Cichowski; T Jacks
Journal:  Cell       Date:  2001-02-23       Impact factor: 41.582

2.  Wnt/Rspondin/β-catenin signals control axonal sorting and lineage progression in Schwann cell development.

Authors:  Tamara Grigoryan; Simone Stein; Jingjing Qi; Hagen Wende; Alistair N Garratt; Klaus-Armin Nave; Carmen Birchmeier; Walter Birchmeier
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-22       Impact factor: 11.205

3.  PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies.

Authors:  Thomas De Raedt; Eline Beert; Eric Pasmant; Armelle Luscan; Hilde Brems; Nicolas Ortonne; Kristian Helin; Jason L Hornick; Victor Mautner; Hildegard Kehrer-Sawatzki; Wade Clapp; James Bradner; Michel Vidaud; Meena Upadhyaya; Eric Legius; Karen Cichowski
Journal:  Nature       Date:  2014-08-13       Impact factor: 49.962

4.  JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells.

Authors:  Paula Kroon; Paul A Berry; Michael J Stower; Greta Rodrigues; Vincent M Mann; Matthew Simms; Deepak Bhasin; Somsundaram Chettiar; Chenglong Li; Pui-Kai Li; Norman J Maitland; Anne T Collins
Journal:  Cancer Res       Date:  2013-07-03       Impact factor: 12.701

5.  Cells of origin in the embryonic nerve roots for NF1-associated plexiform neurofibroma.

Authors:  Zhiguo Chen; Chiachi Liu; Amish J Patel; Chung-Ping Liao; Yong Wang; Lu Q Le
Journal:  Cancer Cell       Date:  2014-10-30       Impact factor: 31.743

6.  The activation of the WNT signaling pathway is a Hallmark in neurofibromatosis type 1 tumorigenesis.

Authors:  Armelle Luscan; Ghjuvan'ghjacumu Shackleford; Julien Masliah-Planchon; Ingrid Laurendeau; Nicolas Ortonne; Jennifer Varin; François Lallemand; Karen Leroy; Valérie Dumaine; Mikael Hivelin; Didier Borderie; Thomas De Raedt; Laurence Valeyrie-Allanore; Frédérique Larousserie; Benoît Terris; Laurent Lantieri; Michel Vidaud; Dominique Vidaud; Pierre Wolkenstein; Béatrice Parfait; Ivan Bièche; Charbel Massaad; Eric Pasmant
Journal:  Clin Cancer Res       Date:  2013-11-11       Impact factor: 12.531

7.  Chromatin-Remodeling-Factor ARID1B Represses Wnt/β-Catenin Signaling.

Authors:  Georgia Vasileiou; Arif B Ekici; Steffen Uebe; Christiane Zweier; Juliane Hoyer; Hartmut Engels; Jürgen Behrens; André Reis; Michel V Hadjihannas
Journal:  Am J Hum Genet       Date:  2015-09-03       Impact factor: 11.025

8.  ARID1B is a specific vulnerability in ARID1A-mutant cancers.

Authors:  Katherine C Helming; Xiaofeng Wang; Boris G Wilson; Francisca Vazquez; Jeffrey R Haswell; Haley E Manchester; Youngha Kim; Gregory V Kryukov; Mahmoud Ghandi; Andrew J Aguirre; Zainab Jagani; Zhong Wang; Levi A Garraway; William C Hahn; Charles W M Roberts
Journal:  Nat Med       Date:  2014-02-23       Impact factor: 53.440

9.  Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.

Authors:  Eric P Rahrmann; Adrienne L Watson; Vincent W Keng; Kwangmin Choi; Branden S Moriarity; Dominic A Beckmann; Natalie K Wolf; Aaron Sarver; Margaret H Collins; Christopher L Moertel; Margaret R Wallace; Bernat Gel; Eduard Serra; Nancy Ratner; David A Largaespada
Journal:  Nat Genet       Date:  2013-05-19       Impact factor: 38.330

10.  PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors.

Authors:  William Lee; Sewit Teckie; Thomas Wiesner; Leili Ran; Carlos N Prieto Granada; Mingyan Lin; Sinan Zhu; Zhen Cao; Yupu Liang; Andrea Sboner; William D Tap; Jonathan A Fletcher; Kety H Huberman; Li-Xuan Qin; Agnes Viale; Samuel Singer; Deyou Zheng; Michael F Berger; Yu Chen; Cristina R Antonescu; Ping Chi
Journal:  Nat Genet       Date:  2014-09-21       Impact factor: 38.330

View more
  34 in total

1.  Distinct signaling programs control human hematopoietic stem cell survival and proliferation.

Authors:  David J H F Knapp; Colin A Hammond; Nima Aghaeepour; Paul H Miller; Davide Pellacani; Philip A Beer; Karen Sachs; Wenlian Qiao; WeiJia Wang; R Keith Humphries; Guy Sauvageau; Peter W Zandstra; Sean C Bendall; Garry P Nolan; Carl Hansen; Connie J Eaves
Journal:  Blood       Date:  2016-11-08       Impact factor: 22.113

Review 2.  In vivo functional screening for systems-level integrative cancer genomics.

Authors:  Julia Weber; Christian J Braun; Dieter Saur; Roland Rad
Journal:  Nat Rev Cancer       Date:  2020-07-07       Impact factor: 60.716

3.  EGFR-Stat3 signalling in nerve glial cells modifies neurofibroma initiation.

Authors:  J Wu; W Liu; J P Williams; N Ratner
Journal:  Oncogene       Date:  2016-10-17       Impact factor: 9.867

Review 4.  Emerging therapeutic targets for neurofibromatosis type 1.

Authors:  James A Walker; Meena Upadhyaya
Journal:  Expert Opin Ther Targets       Date:  2018-05-07       Impact factor: 6.902

5.  Cxcr3-expressing leukocytes are necessary for neurofibroma formation in mice.

Authors:  Jonathan S Fletcher; Jianqiang Wu; Walter J Jessen; Jay Pundavela; Jacob A Miller; Eva Dombi; Mi-Ok Kim; Tilat A Rizvi; Kashish Chetal; Nathan Salomonis; Nancy Ratner
Journal:  JCI Insight       Date:  2019-02-07

Review 6.  The role of ARID1B, a BAF chromatin remodeling complex subunit, in neural development and behavior.

Authors:  Jeffrey J Moffat; Eui-Man Jung; Minhan Ka; Amanda L Smith; Byeong Tak Jeon; Gijs W E Santen; Woo-Yang Kim
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2018-08-24       Impact factor: 5.067

Review 7.  A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies.

Authors:  Ophélia Maertens; Mila E McCurrach; Benjamin S Braun; Thomas De Raedt; Inbal Epstein; Tannie Q Huang; Jennifer O Lauchle; Hyerim Lee; Jianqiang Wu; Timothy P Cripe; D Wade Clapp; Nancy Ratner; Kevin Shannon; Karen Cichowski
Journal:  Cancer Res       Date:  2017-10-09       Impact factor: 12.701

8.  Spatiotemporal Loss of NF1 in Schwann Cell Lineage Leads to Different Types of Cutaneous Neurofibroma Susceptible to Modification by the Hippo Pathway.

Authors:  Juan Mo; Jean-Philippe Brosseau; Zhiguo Chen; Tracey Shipman; Yong Wang; Chung-Ping Liao; Jonathan M Cooper; Robert J Allaway; Sara J C Gosline; Justin Guinney; Thomas J Carroll; Lu Q Le
Journal:  Cancer Discov       Date:  2018-10-22       Impact factor: 39.397

9.  NF1 patient missense variants predict a role for ATM in modifying neurofibroma initiation.

Authors:  Yanan Yu; Kwangmin Choi; Jianqiang Wu; Paul R Andreassen; Phillip J Dexheimer; Mehdi Keddache; Hilde Brems; Robert J Spinner; Jose A Cancelas; Lisa J Martin; Margaret R Wallace; Eric Legius; Kristine S Vogel; Nancy Ratner
Journal:  Acta Neuropathol       Date:  2019-10-29       Impact factor: 17.088

10.  Stat3 loss in mesenchymal progenitors causes Job syndrome-like skeletal defects by reducing Wnt/β-catenin signaling.

Authors:  Prem Swaroop Yadav; Shuhao Feng; Qian Cong; Hanjun Kim; Yuchen Liu; Yingzi Yang
Journal:  Proc Natl Acad Sci U S A       Date:  2021-06-29       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.